Polyclonal Antibody Or Immunogloblin Of Identified Binding Specificity Patents (Class 530/389.1)
Binds hormone, lymphokine, cytokine, or other secreted growth regulatory factor, differentiation factor, intercellular mediator, or neurotransmitter (e.g., insulin, human chorionic gonadotropin, glucagon, cardiodilatin, interleukin, interferon, norepinephrine, epinephrine, acetylcholine, etc.) (Class 530/389.2)
Binds plasma protein, serum protein, or fibrin (e.g., clotting factor, fibrinolytic factor, complement factor, immunoglobulin, apolipoprotein, etc.) (Class 530/389.3)
Binds virus or component or product thereof (e.g., virus-associated antigen, etc.) (Class 530/389.4)
Binds bacterium or similar microorganism or component or product thereof (e.g., pseudomonas, chlamydia, clostridium, bacterium-associated antigen, etc.) (Class 530/389.5)
Binds hematopoietic cell or component or product thereof (e.g., erythrocyte, granulocyte, bone marrow cell, lymphocyte, leukemic cell, hematopoietic cell-surface antigen, hemoglobin, etc.) (Class 530/389.6)
Binds cancer cell or component or product thereof (e.g., cell-surface antigen, etc.) (Class 530/389.7)
Binds drug, hapten, hapten-carrier complex, or specifically-identified chemical structure (e.g., theophylline, digoxin, etc.) (Class 530/389.8)
  • ST2 ANTIGEN BINDING PROTEINS
    Publication number: 20140004107
    Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.
    Type: Application
    Filed: May 17, 2013
    Publication date: January 2, 2014
    Applicant: Amgen Inc.
    Inventor: Amgen Inc.
  • Therapeutic Peptides
    Publication number: 20140004112
    Abstract: The present disclosure provides, in part, compositions comprising peptides immunospecifically binds to defined binding partners, wherein the peptides comprise at least complementarity determining regions relating to the complementarity regions shown in Table 1.
    Type: Application
    Filed: September 12, 2013
    Publication date: January 2, 2014
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Kai W. Wucherpfennig, Bettina Franz, Kenneth F. May,, Jr., Glenn Dranoff, F. Stephen Hodi, Christopher Harvey
  • Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
    Patent number: 8618248
    Abstract: The present invention relates to phosphopeptide compositions and anti-phosphopeptide antibody compositions. Also provided are methods of identifying phosphorylation sites in phosphorylated peptides and phosphorylation site motifs.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: December 31, 2013
    Assignee: President and Fellows of Harvard College
    Inventors: Steven P. Gygi, Judit Villen, Sean Beausoleil
  • Methods of diagnosing pancreatic inflammation by using chemokine PANEC-1 antibodies
    Patent number: 8617551
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode novel expressed chemokines (PANEC-1 and PANEC-2) from human pancreas cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode PANEC-1 and PANEC-2, expression vectors for the production of purified PANEC-1 and PANEC-2, antibodies capable of binding specifically to PANEC-1 and PANEC-2, hybridization probes or oligonucleotides for the detection of PANEC-1- or PANEC-2-encoding nucleotide sequences, genetically engineered host cells for the expression of PANEC-1 and PANEC-2, diagnostic tests for chemokine activation based on PANEC-1- and PANEC-2-encoding nucleic acid molecules and antibodies capable of binding specifically to the protein.
    Type: Grant
    Filed: August 10, 2010
    Date of Patent: December 31, 2013
    Assignee: Incyte Corporation
    Inventors: Roger T. Coleman, Olga Bandman, Craig G. Wilde
  • COMPOSITIONS AND METHODS FOR INCREASING MUSCLE GROWTH
    Publication number: 20130344091
    Abstract: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.
    Type: Application
    Filed: August 29, 2013
    Publication date: December 26, 2013
    Applicant: Novartis AG
    Inventors: Catrin Berger, Tanja Herrmann, Chris Lu, Kelly-Ann Sheppard, Estelle Trifilieff, Stephanie Urlinger
  • MODULATION OF HISTONE H2B MONOUBIQUITINATION AND TREATMENT OF CANCER
    Publication number: 20130344083
    Abstract: Provided are methods and compositions for treatment of cancer. In particular, these methods and compositions may include an inhibitor of a deubiquitinating enzyme. In certain aspects, these methods and compositions may include a modulator of glucose metabolism. Also provided are methods of assaying the glucose content of cells and tissues using detection of uH2B.
    Type: Application
    Filed: March 14, 2013
    Publication date: December 26, 2013
    Inventors: C. Wilson Xu, Yasuyo Urasaki
  • Antibodies Against Tissue Factor Pathway Inhibitor (TFPI)
    Publication number: 20130344090
    Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce clotting time in (a) human FVIII-deficient plasma and/or (b) human whole blood. Such antibodies have utility in the treatment of bleeding disorders and in the stimulation of blood clotting.
    Type: Application
    Filed: August 28, 2013
    Publication date: December 26, 2013
    Applicant: NOVO NORDISK A/S
    Inventors: Ida Hilden, Jes Thorn Clausen
  • COMPOSITIONS FOR SEPARATION METHODS
    Publication number: 20130337528
    Abstract: This invention relates generally to the fields of separation and conversion technologies, and more particularly to materials for use in tangential-flow filtration techniques. The tangential-flow materials are useful in a wide range of separation and conversion processes, including those reliant on reverse osmosis, microfiltration, ultrafiltration, or nanofiltration semipermeable filtration membranes, and provide efficient methods for purifying or producing various target substances, including biopolymer particles for use in tangential-flow filtration.
    Type: Application
    Filed: December 9, 2011
    Publication date: December 19, 2013
    Inventors: Tracy Thompson, Bernd Helmut Rehm, Andrew Brian Herbert, Edward George Saravolac
  • Binding members for interleukin-4 receptor alpha (IL-4Ra) - 173
    Publication number: 20130336978
    Abstract: Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4R?), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4R?, IL-4 and/or IL-13, examples of which are asthma and COPD.
    Type: Application
    Filed: June 6, 2013
    Publication date: December 19, 2013
    Inventors: Per-Olof Fredrik Eriksson, Karin Von Wachenfeldt, Suzanne Cohen, Claire Louise Dobson, Deborah Louise Lane
  • Method for diagnosing pulmonary artery hypertension
    Patent number: 8609356
    Abstract: The invention relates to an in vitro method for detecting pulmonary arterial hypertension (PAHT), or the risk of developing PAHT, which includes determining the presence and/or amount of anti-tenascin C antibodies in a biological sample from a patient.
    Type: Grant
    Filed: April 10, 2009
    Date of Patent: December 17, 2013
    Assignees: Assistance Publique-Hopitaux de Paris, Universite Paris Descartes, Universite Paris-Sud 11
    Inventors: Luc Mouthon, Marc Humbert, Mathieu Tamby
  • Composition for repression of hyperlipidemia and obesity through suppression of intestinal cholesterol absorption
    Patent number: 8609098
    Abstract: Disclosed are a composition for inhibiting hyperlipidemia and obesity through suppression of intestinal cholesterol absorption. An IgY-type antibody derived from yolk to NPC1L1 (Niemann-Pick C1-Like1), contained, as an active ingredient, in the composition of the present invention is linked to NPC1L1 (Niemann-Pick C1-Like1) that is a cholesterol transport protein in the intestines, thus interfering with binding between cholesterol and the transport protein to completely block absorption of cholesterol in the body and thereby prevent hyperlipidemia and obesity.
    Type: Grant
    Filed: April 25, 2011
    Date of Patent: December 17, 2013
    Assignees: Adbiotech Co., Ltd., Bioceltran Co., Ltd.
    Inventors: Sang Ho Jang, Soo Young Choi, Yeom Pyo Lee, Jae Jin An, Hong Gul Cheong, Hyuck Se Kwon, Jeong Keum Park, Doo Yeon Baek
  • BIOINFORMATIC PROCESSES FOR DETERMINATION OF PEPTIDE BINDING
    Publication number: 20130330335
    Abstract: This invention relates to the identification of peptide binding to ligands, and in particular to identification of epitopes expressed by microorganisms and by mammalian cells. The present invention provides polypeptides comprising the epitopes, and vaccines, antibodies and diagnostic products that utilize or are developed using the epitopes.
    Type: Application
    Filed: March 21, 2011
    Publication date: December 12, 2013
    Applicant: IOGENETICS, LLC
    Inventors: Robert D. Bremel, Jane Homan
  • ANTAGONISTIC DR3 LIGANDS
    Publication number: 20130330360
    Abstract: The present disclosure relates to treatment of inflammatory diseases. In particular, the present disclosure relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Application
    Filed: March 1, 2012
    Publication date: December 12, 2013
    Applicant: NOVO NORDISK A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Albrecht Gruhler, Susanne Nedergaard Grell, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • COMPOSITION AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF IRON-RELATED DISORDERS
    Publication number: 20130330343
    Abstract: Provided herein are methods of using the antibodies that bind to RGMc to treat and diagnose iron-related disorders.
    Type: Application
    Filed: December 13, 2012
    Publication date: December 12, 2013
    Applicants: AbbVie Inc., AbbVie Deutschland GmbH & Co. KG
    Inventors: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
  • COMPOSITION AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF IRON-RELATED DISORDERS
    Publication number: 20130330359
    Abstract: Provided herein are antibodies and methods of using the antibodies to treat, prevent, modulate, attenuate and diagnose iron-related disorders.
    Type: Application
    Filed: December 13, 2012
    Publication date: December 12, 2013
    Applicants: AbbVie Inc., AbbVie Deutschland GmbH & Co. KG
    Inventors: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
  • Immunoassay reagents and methods of use thereof
    Patent number: 8603765
    Abstract: The present invention provide reagents and methods of using the reagents, for example, on automated staining devices, that facilitate detection of two or more antigens in a sample simply and efficiently.
    Type: Grant
    Filed: October 27, 2009
    Date of Patent: December 10, 2013
    Assignee: Biocare Medical, LLC.
    Inventor: David Tacha
  • Antigen Binding Proteins that Bind PD-L1
    Publication number: 20130323249
    Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-L1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-L1, PD-L1-binding fragments and derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-L1 related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Application
    Filed: May 31, 2013
    Publication date: December 5, 2013
    Applicant: Sorrento Therapeutics Inc.
    Inventors: Heyue Zhou, Randy Gastwirt, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann
  • Urine Biomarkers For Prediction Of Recovery After Acute Kidney Injury: Proteomics
    Publication number: 20130323751
    Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring urinary proteins can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury. Alternatively, the invention describes signature protein expression profiles to establish the probability of renal to recovery and/or renal non-recovery.
    Type: Application
    Filed: January 20, 2012
    Publication date: December 5, 2013
    Applicant: University of Pittsburgh - of the Common-Wealth System of Higher Education
    Inventors: Kai Singbartl, John A. Kellum, JR.
  • Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
    Patent number: 8598321
    Abstract: This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: December 3, 2013
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Isin N. Geren, Jianlong Lou
  • Anti-IL-6 Receptor Antibody
    Publication number: 20130317203
    Abstract: The present inventors succeeded in discovering specific amino acid mutations in the variable region, framework region, and constant region of TOCILIZUMAB, and this enables to reduce immunogenicity risk and the heterogeneity originated from disulfide bonds in the hinge region, as well as to improve antigen binding activity, pharmacokinetics, stability under acidic conditions, and stability in high concentration preparations.
    Type: Application
    Filed: August 5, 2013
    Publication date: November 28, 2013
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Mika Sakurai, Tetsuo Kojima, Tatsuhiko Tachibana, Hirotake Shiraiwa, Hiroyuki Tsunoda, Atsuhiko Maeda
  • METHOD FOR THE DIAGNOSIS, PROGNOSIS AND MONITORING OF MUSCULAR DEGENERATION
    Publication number: 20130316933
    Abstract: The invention relates to methods based on the quantification of a set of biomarkers, preferably in biological samples isolated from skeletal muscle, for performing the diagnosis, prognosis and/or monitoring of muscular degeneration, preferably muscular degeneration caused by motor neuron diseases, more preferably amyotrophic lateral sclerosis (ALS); and to a kit for the diagnosis, prognosis and monitoring of said type of diseases. The method in the invention for the prognosis and/or monitoring of muscular degeneration makes it possible to determine the rate of progression of said degeneration (fast or slow rate of progression in relation to the normal rate of progression).
    Type: Application
    Filed: December 7, 2011
    Publication date: November 28, 2013
    Applicant: Universidad de Zaragoza
    Inventors: Rosario Osta Pinzolas, Maria Jesus Munoz Gonzalvo, Pilar Zaragoza Fernandez, Ana Cristina Calvo Royo, Raquel Manzano Martinez, Alberto Garcia Redondo, Paz Torre Merino
  • ICE-CLEAVED ALPHA-SYNUCLEIN AS A BIOMARKER
    Publication number: 20130316384
    Abstract: The present disclosure provides ICE-cleaved alpha-synuclein fragments as biomarkers for alpha-synuclein-associated disease or disorder and/or for ICE-regulator therapy.
    Type: Application
    Filed: November 4, 2011
    Publication date: November 28, 2013
    Inventors: Dagmar Ringe, Gregory A. Petsko
  • METHOD FOR TREATING AND PREVENTING TYPE 2 DIABETES
    Publication number: 20130315925
    Abstract: Methods and compositions for treating or preventing type 2 diabetes by inhibiting expression or activity of monoacylglycerol O-acyltransferase 1 (MOGAT1) are disclosed. Also disclosed are methods to identify such compositions.
    Type: Application
    Filed: May 23, 2013
    Publication date: November 28, 2013
    Applicant: BIOMEDCORE, INC.
    Inventors: Hideyoshi HARASHIMA, Yasuhiro HAYASHI, Kazuaki KAJIMOTO
  • Antibodies to apical intestinal receptors and methods of treating metabolic disease
    Patent number: 8592560
    Abstract: The present invention provides pharmaceutical compositions formulated for direct delivery to the GI tract of a patient comprising an antibody specific for a target apical intestinal receptor. The present invention further provides methods of treating diseases and conditions in a patient comprising administering directly to the GI tract of the patient, compositions of the present invention wherein modulation of the target apical intestinal receptor by the antibody treats the condition.
    Type: Grant
    Filed: August 21, 2012
    Date of Patent: November 26, 2013
    Assignee: Avaxia Biologics, Incorporated
    Inventor: Barbara S. Fox
  • METHODS AND MEDICAMENTS FOR THE TREATMENT OF GOUT OR PSEUDOGOUT
    Publication number: 20130302344
    Abstract: The present invention relates to a new method, and the process to manufacture a medicament, for treating gout or pseudogout, comprising administering an effective amount of inhibitors blocking IL-1 or its maturation by the NALP3 inflammasome.
    Type: Application
    Filed: July 16, 2013
    Publication date: November 14, 2013
    Inventors: Virginie Petrilli, Fabio Martinon, Jurg Tschopp, Thibault De Smedt
  • COMPOSITIONS AND METHODS FOR TREATING ALPHAVIRUS INFECTION
    Publication number: 20130295115
    Abstract: Provided herein are compositions and methods for treating a disease or disorder associated with an alphavirus infection. Specifically, the invention relates to administering a Natural Resistance-Associated Macrophage Protein (NRAMP) antagonist to prevent binding or infection of an alphavirus to its host.
    Type: Application
    Filed: November 16, 2011
    Publication date: November 7, 2013
    Inventors: Sara Cherry, Patrick Rose
  • MONOCLONAL ANTIBODIES TARGETING AMYLOID BETA OLIGOMERS
    Publication number: 20130295095
    Abstract: The invention relates to binding molecules capable of specifically recognizing soluble oligomers of N-terminal truncated A? starting with pyroglutamate (A??E), pharmaceutical compositions comprising same, and their respective therapeutic uses. Particularly, the invention relates to an antibody molecule capable of specifically recognizing A? oligomers, wherein said antibody binds and/or detects an epitope as bound and/or detected by antibody PG3-38 9D5H6 as deposited under DSM AC-C3056.
    Type: Application
    Filed: June 3, 2011
    Publication date: November 7, 2013
    Inventors: Thomas Bayer, Oliver Wirths, Henrik Martens, Christian Erck
  • VACCINE ENGINEERING
    Publication number: 20130287838
    Abstract: The method and constructs disclosed and claimed herein allow to control peptide conformation by modulation of the peptide lipidation pattern, spacer and liposome composition, or via co-administration with small molecules. Accordingly, this technology can be applied to the rational design of liposomal vaccines and for the generation of safer and more efficacious therapies for a range of human disease, in particular those based on misfolded proteins.
    Type: Application
    Filed: August 12, 2011
    Publication date: October 31, 2013
    Applicant: AC Immune S.A.
    Inventors: David Hickman, Maria Pilar Lopez-Deber, Andreas Muhs
  • Sp35 Antibodies and Uses Thereof
    Publication number: 20130287796
    Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.
    Type: Application
    Filed: March 14, 2013
    Publication date: October 31, 2013
    Inventors: Sha MI, R. Blake Pepinsky, Zhaohui Shao, Ellen A. Garber, Steven D. Miklasz, Christilyn Graff
  • SIMPLIFIED ONE-POT SYNTHESIS OF [18F]SFB FOR RADIOLABELING
    Publication number: 20130289249
    Abstract: A non-aqueous single pot synthesis of [18F]SFB is set forth. The [18F]SFB produced with this method is then used, for example, to label a peptide or an engineered antibody fragment (diabody) targeting human epidermal growth factor receptor 2 (HER2) as representative examples of labeled compounds for use as an injectable composition to locate abnormal tissue, specifically tumors within an animal or human using a PET scan.
    Type: Application
    Filed: June 21, 2013
    Publication date: October 31, 2013
    Inventors: Sebastian Olma, Clifton Kwang-Fu Shen
  • OSTEOCLASTOGENESIS INHIBITOR CONTAINING ANTI-VDAC ANTIBODY
    Publication number: 20130280260
    Abstract: The present invention provides a therapeutic agent or a preventative agent containing anti-VDAC antibody for diseases in which there is increased activation of osteoclasts, such as rheumatoid arthritis, and an inhibitor of human osteoclast formation containing anti-VDAC antibody.
    Type: Application
    Filed: October 13, 2011
    Publication date: October 24, 2013
    Applicant: TOKYO WOMEN'S MEDICAL UNIVERSITY
    Inventors: Shigeru Kotaka, Yuki Nanke, Toru Yago, Manabu Kawamoto, Hisashi Yamanaka
  • MODIFIED ANTIBODY WITH IMPROVED HALF-LIFE
    Publication number: 20130281677
    Abstract: The present invention relates to antibodies, immunoglobulin constructs or immunoglobulin IgG4 fusion proteins whose in vivo half-lives are increased by the combination of (i) a modified IgG4 Fc region or FcRn binding domain thereof and (ii) a modified IgG4 hinge region sequence.
    Type: Application
    Filed: December 22, 2011
    Publication date: October 24, 2013
    Applicant: Cephalon Australia Pty, Ltd.
    Inventors: David Wilson, Tetsuya Taura
  • HUMAN ANTIBODIES AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISEASE
    Publication number: 20130280167
    Abstract: Specific binding members, particularly human antibodies, particularly recombinant antibodies, and fragments thereof, which are capable of binding to and recognizing neurons in the CNS and eliciting responses in CNS neurons are provided. The antibodies are useful for neuroprotection and in the diagnosis and treatment of conditions associated with nerve damage, injury or degeneration and neurodegenerative disease. The antibodies, variable regions or CDR domain sequences thereof, and fragments thereof of the invention may also be used in therapy in combination with chemotherapeutics, immune modulators, or neuroactive agents and/or with other antibodies or fragments thereof. Antibodies are exemplified by the antibodies IgM12 and IgM42 whose sequences are provided herein.
    Type: Application
    Filed: October 19, 2011
    Publication date: October 24, 2013
    Inventors: Moses Rodriguez, Arthur E. Warrington, Larry R. Pease
  • Diagnostic marker for type 1 diabetes mellitus
    Patent number: 8563327
    Abstract: The present invention provides, as a novel diagnosis marker for type 1 diabetes mellitus, a type 1 diabetes mellitus diagnostic composition comprising alanyl-tRNA synthetase, glycyl-tRNA synthetase, asparaginyl-tRNA synthetase, or tryptophanyl-tRNA synthetase, a diagnostic kit comprising the same, and a diagnostic method using the same. The composition, the kit, and the method, according to the present invention, may be used for early diagnosis and confirmed diagnosis of type 1 diabetes mellitus because type 1 diabetes mellitus can be easily diagnosed from a patient sample.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: October 22, 2013
    Assignees: Seoul National University Hospital, SNU R&DB Foundation
    Inventors: Sang Gyu Park, Kyong Soo Park, Sunghoon Kim
  • Antibodies specific to carbamazepine
    Patent number: 8563713
    Abstract: The present disclosure is directed to antibodies specific to carbamazepine, immunogens used to produce the antibodies, and immunoassay kits and methods for using the antibodies.
    Type: Grant
    Filed: March 22, 2011
    Date of Patent: October 22, 2013
    Assignee: Guangzhou Kingmed Center for Clinical Laboratory
    Inventors: Liuming Yu, Yaoming Liang, Hongbo Li
  • PCSK9 ANTAGONISTS
    Publication number: 20130273069
    Abstract: The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.
    Type: Application
    Filed: April 4, 2013
    Publication date: October 17, 2013
    Inventors: Hong LIANG, Yasmina Noubia ABDICHE, Javier Fernando CHAPARRO RIGGERS, Bruce Charles GOMES, Julie Jia Li HAWKINS, Jaume PONS, Xiayang QIU, Pavel STROP, Yuli WANG
  • Therapeutic Antibodies against ROR-1 Protein and Methods for Use of Same
    Publication number: 20130273073
    Abstract: Therapeutic antibodies having binding specificity for ROR-1 expressed on cancer cells (particularly leukemic and lymphomic cells) and pharmaceutical compositions containing one or more such antibodies for use in treating cancer. Methods for diagnosing such cancers through in vitro detection of binding to ROR-1 protein expressed on putative cancer cells are also provided.
    Type: Application
    Filed: January 13, 2012
    Publication date: October 17, 2013
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thomas J. Kipps, George F. Widhopf, II, Bing Cui
  • NOVEL ANTIBODIES INHIBITING C-MET DIMERIZATION, AND USES THEREOF
    Publication number: 20130273060
    Abstract: The present inventions relates to a process for the selection of anti c-Met antibodies capable to inhibit both ligand-dependent and ligand-independent activation of c-Met. More particularly, said process is based on the inhibition of the c-Met dimerization. In another aspect, the present invention concerns such antibodies and compositions comprising such antibodies for the preparation of a medicament to treat cancer. Diagnosis process and kits are also part of the invention.
    Type: Application
    Filed: November 9, 2012
    Publication date: October 17, 2013
    Inventor: Liliane GOETSCH
  • Method of Providing Disease-Specific Binding Molecules and Targets
    Publication number: 20130266514
    Abstract: Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 10, 2013
    Applicant: University of Zürich
    Inventors: Roger NITSCH, Christoph Hock, Christoph Esslinger, Marlen Knobloch, Kathrin Tissot, Jan Grimm
  • B7-H3 and B7-H4, Novel Immunoregulatory Molecules
    Publication number: 20130267685
    Abstract: The invention provides novel B7-H3 and B7-H4 polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides.
    Type: Application
    Filed: July 18, 2012
    Publication date: October 10, 2013
    Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventor: Lieping Chen
  • ANTIBODY SPECIFICALLY BINDING SYNOVIAL MICROVASCULATURE OF ARTHRITIS PATIENTS
    Publication number: 20130266587
    Abstract: The present invention provides an antigen binding polypeptide which specifically targets the synovial microvasculature of arthritis patients and comprises one or more complementarity determining regions (CDRs) selected from the group consisting of SEQ ID NOs 1 to 4. The present invention also relates to the use of such antigen binding polypeptides and conjugates thereof for use in the diagnosis and treatment of arthritis.
    Type: Application
    Filed: September 30, 2011
    Publication date: October 10, 2013
    Applicant: QUEEN MARY AND WESTFIELD COLLEGE UNIVERSITY OF LONDON
    Inventor: Constantino Pitzalis
  • COMPOSITIONS AND METHODS FOR TREATING CANCER AND NEURODEGENERATIVE DISEASES
    Publication number: 20130266582
    Abstract: The present invention relates to compositions and methods for regulating ROC-mediated death-associated protein kinase (DAPk) activity. The compositions and methods of the present invention are useful for treating or ameliorating cancer as well as pathologies associated with neuronal cell death, such as epilepsy and hypoxia/ischemia acute brain injury. The present invention further relates to screening methods for identifying agents that regulate ROC-mediated DAPk activation.
    Type: Application
    Filed: December 14, 2011
    Publication date: October 10, 2013
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Adi Kimchi, Rodrigo Carlessi
  • ANTIBODY DESIGN USING ANTI-LIPID ANTIBODY CRYSTAL STRUCTURES
    Publication number: 20130261287
    Abstract: Methods for designing optimized antibodies, including optimized humanized or human antibodies, to target bioactive lipids are provided. These methods may be performed in silico and may be intended to enhance binding affinity of an antibody to its original target lipid, and/or to alter binding specificity. Antibodies produced by these methods are also provided, as are methods for using them.
    Type: Application
    Filed: March 11, 2013
    Publication date: October 3, 2013
    Inventors: Roger A. SABBADINI, Jonathan Michael WOJCIAK, Tom HUXFORD
  • ANTIBODIES
    Publication number: 20130259878
    Abstract: The present disclosure provides antibodies, including isolated monoclonal antibodies, which specifically bind to CDH17 with high affinity. Nucleic acid molecules encoding CDH17 antibodies, expression vectors, host cells and methods for expressing CDH17 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the CDH17 antibodies are also provided. Methods for detecting CD-H17, as well as methods for treating carious cancers, including gastric cancer, pancreatic cancer, colon cancer and colorectal cancer, are disclosed.
    Type: Application
    Filed: October 19, 2011
    Publication date: October 3, 2013
    Applicant: OXFORD BIOTHERAPEUTICS LTD
    Inventor: Jonathan Alexander Terrett
  • ANTI-CXCR3 ANTIBODIES
    Publication number: 20130251733
    Abstract: The present disclosure provides anti-CXCR3 antibodies and methods of using the antibodies to diagnose and/or treat CXCR3-associated disorders such as diabetes mellitus type I (T1D), particularly new-onset T1D. In certain embodiments, disclosed herein are CXCR3 neutralizing antibodies.
    Type: Application
    Filed: January 18, 2013
    Publication date: September 26, 2013
    Applicant: Genzyme Corporation
    Inventors: Michele Youd, Jennifer Tedstone, Tracey Lodie, Karen B. Carter, Timothy D. Connors, Jason Robert Pinckney, Elizabeth Masterjohn, Ruiyin Chu
  • Tau Acetylation in the Pathogenesis of Alzheimers Disease and Other Related Tauopathies
    Publication number: 20130251731
    Abstract: The present invention relates to biomarkers and diagnostic methods for Alzheimer's disease and other neurodegenerative disorders. The invention also provides compositions for detecting the biomarker as well as compositions and methods useful for treating Alzheimer's disease and other neurodegenerative disorders.
    Type: Application
    Filed: March 13, 2013
    Publication date: September 26, 2013
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Virginia M.Y. Lee, Todd J. Cohen, John Q. Trojanowski
  • Toll-like receptor 3 antagonists
    Patent number: 8540986
    Abstract: Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.
    Type: Grant
    Filed: April 29, 2010
    Date of Patent: September 24, 2013
    Assignee: Janssen Biotech, Inc.
    Inventors: Mark Cunningham, Yiqing Feng, Katharine Heeringa, Jinquan Luo, Robert Rauchenberger, Mark Rutz, Lani San Mateo, Robert Sarisky, Raymond Sweet, Fang Teng, Alexey Teplyakov, Sheng-Jiun Wu
  • Antibodies that bind polypeptides involved in the process of bone remodeling
    Patent number: 8540988
    Abstract: This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling, variants and derivatives of the polynucleotides and corresponding polypeptides, uses of the polynucleotides, polypeptides, variants and derivatives, and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are the isolation and identification of polynucleotides, polypeptides variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: September 24, 2013
    Assignee: Alethia Biotherapeutics Inc.
    Inventors: Roy Rabindranauth Sooknanan, Gilles Bernard Tremblay, Mario Filion
  • Humanized Anti-CXCR5 Antibodies, Derivatives Thereof And Their Use
    Publication number: 20130243793
    Abstract: The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders.
    Type: Application
    Filed: March 11, 2013
    Publication date: September 19, 2013
    Inventors: Renata Lee, Vincent Mikol, Elizabeth Allen, Norman Ruetsch, Beatrice Cameron, Thomas Oligino, Nicholas Baurin
  • ANTIBODIES TO THE CHEMOKINE RECEPTOR XCR1
    Publication number: 20130245236
    Abstract: The present invention relates to an antibody binding to murine XCR1. Furthermore, the present invention relates to a nucleic acid molecule encoding for said antibody, a vector comprising said nucleic acid molecule and a host cell comprising said vector. The present invention further embraces a method for producing the antibody. Moreover, the present invention claims the use of the antibody and a kit for detecting murine XCR1+ cells and/or separating murine XCR1+ cells from other cells.
    Type: Application
    Filed: March 13, 2013
    Publication date: September 19, 2013
    Inventor: Richard KROCZEK